Immunic Stock Soars 23.53% on Wedbush Target Cut

On May 30, 2025, Immunic's stock surged by 23.53% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Immunic's stock price target was recently adjusted by Wedbush, reducing it from $61 to $14. This revision comes after the company was initially rated as "outperform" with a $40 stock price target. The change in target price reflects the evolving market sentiment and potential challenges the company may face in the near future.

Despite the recent volatility, Immunic continues to be a focal point for investors, with its innovative approach to biotechnology and potential breakthroughs in the field of immunology. The company's strategic initiatives and partnerships are expected to drive future growth and stability, making it a stock to watch in the coming months.